- Altimmune’s GLP-1-based shot cuts drinking in patients with alcoholismAltimmune said Tuesday that its GLP-1/glucagon agonist reduced drinking in people with moderate-to-severe alcohol use disorder in a mid-stage study. Patients in the Phase 2 RECLAIM trial took a w…Endpoints · 14m ago↗ source
- STAT+: Preliminary trial results suggest a path to a safer Alzheimer’s treatmentProMIS Neurosciences is trying to design a safer amyloid-clearing drug for Alzheimer's. Early results suggest it might be on to something.STAT · 1h ago↗ source
- After PCOS became PMOS, there’s hope for new awareness among Black and Latina womenGrowing awareness of a painful endocrine disorder now named PMOS is good news for women of color, who have high prevalence and low diagnosis.